The effects of bupropion on negative symptoms in schizophrenia

Determine the efficacy of bupropion versus placebo in subjects with negative symptoms of schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013100114850N1

Enrollment

Registered

2013-10-18

Start date

2011-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Negative symptoms in schizophrenia.

Interventions

Intervention 1: Bupropion (100 mg TDS,12 weeks) in intervention group. Intervention 2: Placebo( simirarly to bupropion,TDS,12 weeks) in control group.

Treatment - Drugs

Bupropion (100 mg TDS,12 weeks) in intervention group

Placebo( simirarly to bupropion,TDS,12 weeks) in control group

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion:age of 15 to 60 years old, presence of negative symptoms Exclusion:presence of depression,substance abuse,suicidal ideation,sever psychosis,sever medical illness,pregnancy and lactation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Negative symptoms. Timepoint: Onset and end of trial. Method of measurement: Scale for the assessment of negative symptoms inquirement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeda shariat

Yazd medical science university of shahid sadughi

Nedashariat@yahoo.com+98 35 2623 2004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026